Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.

@article{Keystone2012MultipleCO,
  title={Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.},
  author={Edward Clark Keystone and Stanley B. Cohen and P T J Emery and Joel M. Kremer and Maxime R Dougados and James E Loveless and Carol Chung and Pamela Wong and Patricia B. Lehane and Helen Tyrrell},
  journal={The Journal of rheumatology},
  year={2012},
  volume={39 12},
  pages={2238-46}
}
OBJECTIVE This 5-year observational posthoc analysis of the REFLEX study and its open-label extension assessed clinical efficacy, radiographic response, and safety of rituximab (RTX) in patients with rheumatoid arthritis (RA) who had an inadequate response to tumor necrosis factor (TNF) inhibitors. METHODS Patients in REFLEX were originally randomized to placebo (PBO) + methotrexate (MTX; PBO-randomized) or RTX + MTX (RTX-randomized). PBO-randomized patients were rescued with RTX as… CONTINUE READING